TL1A, is upregulated in inflamed intestinal tissues and promotes the activation of lymphocytes and fibroblasts, driving chronic inflammation and tissue remodeling. Tulisokibart’s blockade of TL1A-DR3 signaling aims to reduce immune cell infiltration, cytokine production, and fibrotic responses, offering a targeted approach for patients with moderate-to-severe IBD who are refractory to conventional therapies.